Q1 2022 Results

Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors ligelizumab - IgE inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04984876 (CQGE031G12301) Food allergy Phase 3 486 1. Proportion of participants who can tolerate a single dose of ≥ 600 mg (1044 mg cumulative tolerated dose) of peanut protein without dose-limiting symptoms at Week 12 Arm 1: Experimental ligelizumab 240 mg subcutaneous injection for 52 weeks Arm 2: Experimental ligelizumab 120 mg subcutaneous injection for 52 weeks Arm 3: Experimental Placebo 8 weeks and ligelizumab 120 mg Arm 4: Placebo subcutaneous injection for first 8 weeks and ligelizumab 120 mg subcutaneous injection for 44 weeks Arm 5: Experimental Placebo 16 weeks and ligelizumab 120 mg/240 mg subcutaneous injection for 36 weeks Arm 6: Experimental Placebo 8 weeks and ligelizumab 240 mg subcutaneous injection for 44 weeks Participants with a medically confirmed diagnosis of IgE-mediated peanut allergy Target Patients Read-out Milestone(s) 2025 Publication TBD 87 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine

View entire presentation